Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Australian Clinical Labs Ltd ( (AU:ACL) ).
Allan Gray Australia Pty Ltd, a substantial holder in Australian Clinical Labs Limited, has increased its voting power from 7.50% to 8.79% as of May 30, 2025. This change in interest may influence the company’s governance and strategic decisions, potentially impacting stakeholders and the company’s market positioning.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited operates within the healthcare industry, focusing on providing pathology services. The company is a key player in the Australian market, offering a range of diagnostic services to support clinical decision-making.
Average Trading Volume: 982,849
Technical Sentiment Signal: Sell
Current Market Cap: A$553.8M
Find detailed analytics on ACL stock on TipRanks’ Stock Analysis page.